Precision Bio Complete Clinical Response in 1st Patient in Ongoing Phase 1/2 Gene Deficiency Trial

 Treatment with ECUR-506 resulted in a complete clinical response from three months post exposure to the end of study (six months post exposure)

- ECUR-506 was generally well tolerated with no significant clinical safety concerns

- Insertion of a functional OTC gene through ARCUS in vivo gene editing may provide lasting clinical benefit for children with OTC deficiency who are in dire need of effective treatments

https://www.businesswire.com/news/home/20250109651360/en/